Opioid Agonists and the Analgesic Effect

The opioid system is one of the most ancient and complex neuropharmacological systems in vertebrate biology. Endogenous opioid peptides — endorphins, enkephalins, dynorphins, and endomorphins — acting through three receptor types (mu, kappa, and delta opioid receptors) modulate pain processing, reward, stress responses, and homeostatic regulation throughout the nervous system and peripheral tissues. Exogenous opioid agonists tap into this system to produce analgesia — and, in excessive doses or in individuals with certain vulnerabilities, to produce dependence, respiratory depression, and death. Understanding the pharmacology of opioid agonists is essential both for effective pain management and for understanding the opioid epidemic.

Opioid Receptors: Structure and Distribution

The three classical opioid receptor types — mu (MOR, OPRM1), delta (DOR, OPRD1), and kappa (KOR, OPRK1) — are Gi/Go-coupled GPCRs expressed throughout the central nervous system, peripheral sensory neurons, and immune cells. All three are inhibitory receptors: agonist binding activates Gi/Go, inhibiting adenylyl cyclase (reducing cAMP), activating inwardly rectifying potassium channels (GIRK, hyperpolarizing the cell), and inhibiting voltage-gated calcium channels (reducing neurotransmitter release). The net effect in pain-processing circuits is reduced transmission of nociceptive signals at multiple levels: the spinal dorsal horn (where primary afferent nociceptors synapse onto ascending pain pathways), supraspinal pain control centers (periaqueductal gray, rostral ventromedial medulla), and peripheral primary afferent terminals.

Mu opioid receptors mediate the principal analgesic, euphoric, and respiratory depressant effects of clinical opioids. Most clinically used opioid agonists — morphine, oxycodone, hydromorphone, fentanyl, methadone — are mu opioid receptor agonists. Kappa agonists (dynorphins endogenously; butorphanol, nalbuphine partly clinically) produce analgesia but also dysphoria, sedation, and psychotomimetic effects. Delta agonists are under investigation for chronic pain but lack current clinical approvals.

Pharmacokinetics and Clinical Opioids

Morphine is the prototypical opioid agonist and the reference against which others are compared (equianalgesic dosing tables express all opioids as morphine equivalents). It has moderate oral bioavailability (~30%), rapid onset of action when given parenterally (3–5 minutes IV), a plasma half-life of 2–4 hours, and active metabolites — morphine-6-glucuronide (M6G) is more potent than morphine itself and accumulates in renal impairment, necessitating dose adjustment. Morphine acts as a full agonist at MOR with high intrinsic efficacy.

Fentanyl is approximately 100 times more potent than morphine, highly lipophilic (enabling transdermal delivery via patches and transmucosal delivery for breakthrough cancer pain), and has a rapid onset when given IV (~90 seconds) due to rapid CNS penetration. It is metabolized by CYP3A4 to inactive norfentanyl; its toxicity is dramatically potentiated by CYP3A4 inhibitors. Illicitly manufactured fentanyl (IMF) and its more potent analogues (carfentanil, nitazenes) are driving the current wave of overdose deaths in North America and Europe due to their extreme potency and the difficulty of predicting lethal doses in street drug supplies.

Opioid-Induced Side Effects

The same mu opioid receptors that mediate analgesia also mediate the limiting adverse effects. Respiratory depression — the principal cause of opioid overdose death — results from MOR activation in the pre-Bötzinger complex (preBötC), the brainstem respiratory rhythm generator. Nausea and vomiting reflect MOR activation in the chemoreceptor trigger zone of the area postrema. Constipation arises from peripheral MOR activation in enteric neurons, reducing gut motility; this effect does not develop tolerance as rapidly as analgesia, making opioid-induced constipation a persistent problem requiring active management (laxatives, or peripherally restricted MOR antagonists — methylnaltrexone, naloxegol). Sedation, euphoria, and addiction potential all reflect central MOR activation in limbic and cortical reward circuits.

Naloxone: The Opioid Antagonist

Naloxone (Narcan) is a pure competitive opioid receptor antagonist at mu, delta, and kappa receptors that has essentially no agonist activity (zero or near-zero intrinsic efficacy). By competing with opioid agonists for receptor binding, naloxone rapidly reverses opioid-induced respiratory depression, sedation, and miosis. Its short duration of action (30–90 minutes) is shorter than most opioid agonists, necessitating repeat dosing or continuous infusion in overdose management. Intranasal formulations of naloxone for bystander use (Narcan nasal spray) have saved hundreds of thousands of lives in the opioid overdose crisis. Buprenorphine, discussed in our article on partial agonists, demonstrates how partial agonism at MOR provides an important harm-reduction profile for opioid use disorder treatment.

For more information, visit our homepage or our resources section.